Cite
HARVARD Citation
Chu, Y. et al. (n.d.). OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL. Leukemia research. pp. S14-. [Online].